The two drugmakers recalled the extended-release tablets after detecting unacceptable levels of N-Nitrosodimethylamine, a probable human carcinogen.
Teva is recalling 14 lots of its metformin hydrochloride extended-release tablets in the U.S., including their 500 mg and 750 mg bottles.
Marksans Pharma Limited, which is based in India, is recalling one lot of its extended-release metformin tablet in the U.S.
The recalls come after the FDA determined May 28 that there were unacceptable levels of N-Nitrosodimethylamine in metformin extended-release tablets.
Two other drugmakers, Apotex and Amneal Pharmaceuticals have both recalled their extended-release tablets after being asked to do so by the FDA.
The agency had asked five drugmakers to voluntarily recall their products.
More articles on pharmacy:
Pharmacist salaries across the most common work settings
FDA asks 5 drugmakers to recall metformin products
Remdesivir could make billions for Gilead, analyst says
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.